Month: August 2026

Kratos Defense & Security (KTOS) – That Didn’t Take Long

Posted on by [email protected]


Friday, August 07, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

From Opportunity to Reality. Less than 48 hours after speaking of these potential opportunities (among a bunch of other opportunities), Kratos has been awarded a U.S. Army contract related to the Javelin Missile System, and Kratos partner Boeing announced it has been awarded a funding contract to begin supplying long-range JDAMs that incorporate Kratos turbojet engines.

JDAM. The Air Force awarded Boeing a $75 million production contract to begin supplying long-range JDAMs. The long-range variant adds a Kratos TDI-J85 turbojet providing 200 pounds of thrust to enable jets to attack from a much safer distance. The 2027 National Defense Authorization Act includes about $277 million for 1,150 upgraded JDAM guidance tail kits with M-Code GPS for the legacy munitions. Industry experts note the new version will cost far less than more exquisite stand-off munitions, so they should be considered as an affordable mass capability, playing right into Kratos’ key strengths, in our opinion.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Information Services Group (III) – Post Call Commentary

Posted on by [email protected]


Friday, August 07, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Strong Quarter. ISG had a strong second quarter with both revenue and adjusted EBITDA above expectations. The second quarter marks the seventh quarter in a row that adjusted EBITDA has grown by double digits. Expanding margins reflect the continued evolution of ISG’s business toward higher-value advisory work, growth in recurring revenues, and increasing leverage from AI-enabled delivery, in our view.

AI Opportunity. AI is a tailwind for ISG. ISG is taking advantage of the need for AI, reshaping the business as an AI-centered technology research and advisory firm to drive stronger client demand and improve how services are delivered. Nearly half of ISG’s clients generated AI-related revenue during the quarter. Growth was broad-based across industries, led by consumer, health sciences, and manufacturing.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

EuroDry (EDRY) – Second Quarter 2026 Review and Outlook

Posted on by [email protected]


Friday, August 07, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

2Q 2026 Financial Results. EuroDry Ltd. reported strong 2Q 2026 financial performance compared to the prior year period, driven primarily by a favorable dry bulk market and higher time charter equivalent (TCE) rates. Total net revenues increased 57% year-over-year to $17.7 million, while average time charter equivalent rates more than doubled to $20,398 per day compared with $10,428 per day during the prior year period. Adjusted net income attributable to controlling shareholders amounted to $6.9 million, or $2.44 per diluted share, compared to a net loss of $3.0 million, or $(1.10) per diluted share, in the prior year period. Adjusted EBITDA increased to $11.7 million compared to $1.9 million during the prior year period, reflecting strong operating leverage as TCE rates increased. We had projected 2Q revenue and adj. EBITDA of $17.4 million and $9.3 million, respectively.

Strong Operational Quarter. Fleet utilization improved to 100.0% compared to 99.3% during the prior year period, with commercial utilization at 100%, reflecting minimal downtime and effective charter execution. Vessel operating expenses declined modestly to $6,608 per day compared to $6,785 per day during the prior year period, while total operating expenses decreased to $7,444 per day compared to $7,539 during the second quarter of 2025.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

E.W. Scripps (SSP) – Execution Becomes the Investment Story

Posted on by [email protected]


Friday, August 07, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q2 results fell short of expectations, reflecting both cyclical and structural pressures. Revenue declined 9.2% year over year, as retransmission blackouts with Comcast and DirecTV reduced distribution revenue by approximately $26.7 million, while continued weakness in national advertising and audience measurement challenges weighed on the Networks business. 

Transformation efforts are accelerating and should improve earnings power over time. Management now expects to achieve approximately $100 million in annualized run-rate cost savings by year-end as part of its broader plan to deliver $125–150 million of incremental enterprise EBITDA by 2028 through AI, automation, and operational efficiencies. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Why Friday’s Jobs Report Is a Bigger Deal for Small Caps Than the S&P 500

Posted on by [email protected]

Everyone will watch Friday’s jobs report for what it says about the Fed. Small-cap investors should watch it more closely than anyone — because no corner of the market is more exposed to the number, and none needs a more specific outcome.

Here’s the setup. Economists expect the US economy added about 80,000 jobs in July, with unemployment holding steady at 4.2%. That would be a step up from June’s soft 57,000. The supporting data this week has been a mixed bag that mostly leans benign: job openings barely moved, ADP’s private hiring gauge came in light but wages for job-switchers ticked higher, and the outplacement firm Challenger reported fewer planned layoffs and more planned hiring. A Bank of America analysis even suggested payroll growth may have picked up in July, with the gains skewed toward lower-income households — whose after-tax pay is now growing faster than higher earners’ for the first time since late 2024.

So why does this matter more to small caps than to the giants at the top of the index?

Because small companies live and die on the cost of capital. They carry more floating-rate debt, they refinance more often, and they lack the fortress balance sheets and overseas cash piles that insulate the mega-caps. When the Fed’s rate path shifts, it moves small caps first and hardest. And the jobs report is the single biggest input into that path. They’re also overwhelmingly domestic, so the health of the US labor market is the health of their customers.

Now the part that makes Friday genuinely tricky: small caps need a Goldilocks number.

Too hot, and the story turns against them. A blowout print sends Treasury yields higher and pushes rate cuts further out — exactly what played out midweek, with yields climbing and the Russell 2000 slipping while the Dow gave back its record run. Too cold, and a different fear takes over: small caps are the most economically sensitive part of the market, so a number weak enough to whisper “recession” hits them harder than anyone. What they want is the narrow middle — cooling enough to keep the Fed cutting, steady enough to keep the expansion intact.

The timing raises the stakes. This lands just as small-cap earnings growth has finally started outpacing large-caps and the market’s rally is broadening beyond a handful of AI names. A friendly jobs number could be the spark that extends that rotation. An ugly one could smother it before it gets going.

One caution worth keeping in view: don’t overtrade a single data point. Payroll figures have been noisy and heavily revised lately — June disappointed, earlier months were marked down — and the reliability of the data itself has been a live debate. One print is a data point, not a trend.

Still, watch Friday closely. The headlines will fixate on the top-line number and the Fed. The more interesting question sits one rung down the market-cap ladder: whether small caps get the number they need to keep their moment alive.

Release – BODi Announces Second Amendment to Credit Facility

Posted on by [email protected]
Placeholder Company

Research News and Market Data on BODI

August 6, 2026

EL SEGUNDO, Calif.–(BUSINESS WIRE)– The Beachbody Company, Inc. (NASDAQ: BODI) (“BODi” or the “Company”), the proactive wellness company delivering nutrition, supplements, and proven fitness programs that help people take control of their health inside and out, today announced it has entered into a second amendment to its credit agreement with Tiger Finance, LLC, as administrative agent and collateral agent. This modification continues to enhance the Company’s financial flexibility through amended covenant terms.

The amendment further streamlines the financial covenant structure, eliminates the billings fixed charge coverage ratio covenant, and adjusts certain other financial covenants, including the minimum digital subscriptions level and the Three Month Total Billings Target. The amended covenants for the Three Month Total Billings target and the minimum Digital Subscriptions level will not be tested if the Company’s cash balance is above $22.5 million. The second amendment reduced the cash balance required to not test these two covenants by approximately $7 million as of the date of the second amendment. The Company must maintain a minimum liquidity level of $18 million, which will decrease by approximately $0.2 million monthly beginning March 1, 2027 to $16 million.

Mark Goldston, Executive Chairman of The Beachbody Company, commented, “We continue to value our relationship with Tiger Finance as a creative, resourceful and supportive partner to BODi. This amendment gives us additional flexibility to execute on our growth strategies as we build on the progress we’ve made in 2026.”

Carl Daikeler, Co-Founder and Chief Executive Officer added: “This amendment reflects the continued strengthening of our balance sheet and supports our ability to invest in growth, including our nutrition and retail initiatives, without compromising the financial discipline that has defined our turnaround.”

The Company’s cash position of $36.6 million on March 31, 2026, exceeded its $23.6 million debt level by $13.0 million. This strong financial position demonstrates the success of its financial transformation and positions BODi for its planned growth initiatives in 2026.

About BODi and The Beachbody Company, Inc.

BODi is the proactive wellness company delivering nutrition, supplements and proven fitness programs that help people take control of their health inside and out. With nearly three decades of experience, BODi, formerly Beachbody, has evolved from a leader in home fitness into a comprehensive health and fitness ecosystem designed to help people achieve their goals and lead healthier, more fulfilling lives. Anchored by science-backed nutrition solutions like Shakeology and supported by its portfolio of proven fitness and habit-building programs, including P90X and INSANITY, BODi is creating a more accessible and effective path to long-term health.

Since its inception, BODi has supported more than 30 million customers in achieving lasting results. The company continues to innovate across nutrition and digital fitness to deliver simple, proven solutions for modern lifestyles.

To subscribe and shop, visit BODi.com. For company and investor information, please visit TheBeachbodyCompany.com.

Investor Relations
[email protected]

Source: The Beachbody Company, Inc.

Release – NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada

Posted on by [email protected]

Research News and Market Data on NRSN

Final meeting minutes reflect alignment with Health Canada on the planned content and structure of the ALS submission

CAMBRIDGE, Mass., Aug. 6, 2026 /PRNewswire/ — NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced that it is targeting December 2026 for the filing of a New Drug Submission (“NDS”) with Health Canada for PrimeC, its lead therapeutic candidate for amyotrophic lateral sclerosis (“ALS”).

The filing target follows the successful finalization of the Pre-NDS process with Health Canada and the associated meeting minutes. The discussions with Health Canada provided alignment regarding the content and structure of the submission. Health Canada has also indicated that it has no concerns with the Company’s proposed filing timeline and advised the Company to target early December.

NDS is the Canadian equivalent of a New Drug Application (NDA) in the United States. Following the successful completion of the Pre-NDS process, the application will undergo an administrative screening and, if accepted for review, a comprehensive scientific evaluation. Health Canada’s target review timeline for a standard NDS is approximately 300 days following acceptance for review.

“We now have an alignment with the Canadian regulator and a clear operational target,” said Alon Ben-Noon, Chief Executive Officer of NeuroSense. “Our team is advancing the remaining clinical, biomarker, manufacturing and regulatory components of the NDS, with the objective of filing in December 2026. Canada represents an important potential market for PrimeC and, more importantly, an opportunity to bring a promising therapy to people living with ALS.”

Significant need for additional ALS treatments in Canada

Based on publicly reported Canadian data1, over 3,000 Canadians are currently living with ALS, and approximately 1,000 Canadians are diagnosed with the disease each year. Given the limited treatment options available and their modest clinical benefit, ALS remains a progressive and fatal neurodegenerative disease with substantial unmet medical need.

Health Canada-approved treatments for the broad ALS population include riluzole and edaravone. Based on the publicly reported Canadian list price assessed by the Canadian Agency for Drugs and Technologies in Health, now Canada’s Drug Agency, oral edaravone carries an estimated annual drug-acquisition cost of approximately C$120,000 (approximately US$85,000) per patient. Actual prices paid by public drug plans may differ because of confidential pricing arrangements and negotiated rebates.

NeuroSense believes these market dynamics underscore both the considerable healthcare burden associated with ALS and the need for additional therapies capable of meaningfully affecting disease progression and survival.

PrimeC clinical evidence

The planned NDS will be supported by the totality of evidence generated through NeuroSense’s Phase 2b PARADIGM clinical program, including:

  • Achievement of the study’s prespecified primary TDP-43 biomarker endpoint;
  • Long-term clinical outcomes demonstrating consistent effects on ALSFRS-R decline;
  • Statistically significant ~15-month median survival benefit (HR 0.35, p=0.0037);
  • Consistent findings across PrimeC’s multi-pathway biomarker program; and
  • A favorable safety and tolerability profile during extended treatment and follow-up.

NeuroSense is progressing the Canadian NDS in parallel with preparations for PARAGON, its confirmatory Phase 3 clinical study of PrimeC in ALS.

About NeuroSense

NeuroSense Therapeutics is a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. The Company’s lead product candidate, PrimeC, is a novel oral therapy designed to target multiple key biological pathways underlying disease progression, including neuroinflammation, oxidative stress and dysregulated iron metabolism.

NeuroSense has recently completed analysis of long-term follow-up data from its Phase 2b PARADIGM study in ALS, supporting meaningful slowing of disease progression. The Company also reported significant biological activity across multiple biomarkers associated with ALS, including microRNAs, supporting PrimeC’s multi-target mechanism of action and representing a potentially important advance in the treatment of ALS.

NeuroSense has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a pivotal Phase 3 clinical trial (PARAGON) in ALS, which is expected to enroll approximately 300 participants, primarily in the United States.

For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.

About PrimeC

PrimeC, NeuroSense’s lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to target several key mechanisms that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid (“RNA”) regulation, with the potential to inhibit disease progression.

About ALS

Amyotrophic lateral sclerosis (“ALS”) is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the timing of the filing of the NDS with Health Canada for PrimeC, the timing of review by Health Canada of the NDS and the commercial potential of PrimeC. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include risks of delay in the planned filing of the NDS with Health Canada; the risk of delay in the review by Health Canada of the NDS; the risk that Health Canada will not approve the NDS; the uncertainty regarding the commercial potential of PrimeC; uncertainty regarding outcomes and the timing of current and future clinical trials; the risk that PrimeC will not advance towards later-stage development, timing for reporting data, including from the study of PrimeC in Alzheimer’s disease; that the study will not be successful; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense’s filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading “Risk Factors” in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 31, 2026 and NeuroSense’s subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.

1 https://news.ontario.ca/en/release/1003213/ontario-first-in-canada-to-provide-coverage-for-new-als-treatment?utm_source=chatgpt.com

Logo – https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg

SOURCE NeuroSense

For further information: For further information: Email: [email protected] | Tel: +972 (0)9 799 6183

Release – Virginia Awards Conduent Contract to Manage and Modernize Medicaid Program Delivery Systems

Posted on by [email protected]

Research News and Market Data on CNDT

Award extends Conduent’s 25-year relationship with Virginia Medicaid and accelerates modernization efforts

August 06, 2026

Government Healthcare Services

Conduent Incorporated (Nasdaq: CNDT), a global technology-driven business solutions and services company, today announced that the Virginia Department of Medical Assistance Services (DMAS) has awarded the company a contract to continue operating, and modernize, the Commonwealth’s systems that support Virginia Medicaid. The contract, which spans up to 14 years, extends Conduent’s relationship with Virginia’s Medicaid program that began in 2001.

Under the new agreement, Conduent will use its modular Conduent Medicaid Suite (CMdS) to modernize Virginia’s Medicaid Enterprise Systems and Fiscal Agent Services Solution. These entail claims processing, finance, call center services, reporting, and other core functions. This transition to an integrated, dynamic solution will help DMAS improve access to information, reduce fraud risks, and strengthen program performance. Members, providers, and staff will benefit from enhanced user experiences, supporting better health outcomes for the approximately 1.6 million Virginians enrolled in Medicaid.

Conduent will also deploy Conduent CXNow , its cloud-based Customer Experience-as-a-Service platform used by government agencies and commercial clients. Powered by AI, automation, and analytics, CXNow will streamline customer interactions across phone and chat, expand self-service options, and improve overall service quality. For the Commonwealth, these enhancements will drive additional cost savings and operational efficiency.

“We are honored to continue our long-standing collaboration with Virginia to enhance Medicaid outcomes through modernization, advanced technologies, and improved business processes,” said Anna Sever, President, Government Solutions at Conduent. “Through strong collaboration and teamwork, we are committed to delivering exceptional value to the Commonwealth and improving the lives of Virginians.”

The new contract includes a two-year design and implementation phase, followed by a six-year base term and six one-year options. It also includes continued management of incoming and outgoing mail services supporting the Medicaid program.

Conduent’s Government Solutions supports government healthcare programs across the country, delivering a range of innovative solutions such as Medicaid management and provider services, pharmacy benefits management, eligibility and enrollment support, and case management solutions. The business also provides agencies with government payments and child support services. In 2025 alone, Conduent processed over 454 million Medicaid claims and disbursed approximately $80 billion in government benefit payments.

About Conduent

Conduent delivers digital business solutions and services spanning the commercial, government and transportation spectrum – creating valuable outcomes for its clients and the millions of people who count on them. The Company leverages cloud computing, artificial intelligence, machine learning, automation and advanced analytics to deliver mission-critical solutions. Through a dedicated global team of approximately 48,000 associates, process expertise and advanced technologies, Conduent’s solutions and services digitally transform its clients’ operations to enhance customer experiences, improve performance, increase efficiencies and reduce costs. Conduent adds momentum to its clients’ missions in many ways including disbursing approximately $80 billion in government payments annually, enabling approximately 2.0 billion customer service interactions annually, empowering millions of employees through HR services every year and processing over 14 million tolling transactions every day. Learn more at www.conduent.com .

Note: To receive RSS news feeds, visit www.news.conduent.com . For open commentary, industry perspectives and views, visit https://x.com/Conduent , http://www.linkedin.com/company/Conduent or http://www.facebook.com/Conduent .

Trademarks

Conduent is a trademark of Conduent Incorporated in the United States and/or other countries. Other names may be trademarks of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260806411810/en/

Media:
Neil Franz, Conduent, [email protected] , +1-240-687-0127

Investor Relations:
Conduent, [email protected]

Media Contacts

Neil Franz

Conduent

[email protected]

+1-240-687-0127

Release – Snail, Inc. Sets Second Quarter 2026 Conference Call for Tuesday, August 11, 2026 at 4:30 p.m. ET

Posted on by [email protected]
Snail, Inc logo

Research News and Market Data on SNAL

August 6, 2026 at 8:30 AM EDT

PDF Version

CULVER CITY, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) — Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, will hold a conference call and webcast on Tuesday, August 11, 2026 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss its financial results for the second quarter ended June 30, 2026.

Snail Games management will host the conference call and webcast, followed by a question-and-answer period. Participants may listen to the live webcast and replay via the link here or on the Company’s investor relations website at https://investor.snail.com/.

About Snail, Inc.
Snail, Inc. (Nasdaq: SNAL) is a leading, global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs, and mobile devices. For more information, please visit: https://snail.com/.

Investor Contact:
John Yi and Steven Shinmachi
Gateway Group, Inc.
949-574-3860
[email protected]

Release – Kratos Receives U.S. Army Contract to Develop a Next-Generation Seeker for the Javelin Missile System

Posted on by [email protected]
Primary Logo

Research News and Market Data on KTOS

August 6, 2026

PDF Version

SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a technology company in defense, national security, and global markets, announced today that it has been awarded a contract by the U.S. Army Combat Capabilities Development Command (DEVCOM) Command, Control, Communications, Computers, Cyber, Intelligence, Surveillance and Reconnaissance (C5ISR) Center to develop an Enhanced Seeker for the Javelin Close Combat Missile System.

Kratos will develop, build, and test a next-generation infrared seeker that addresses obsolescence in the current Javelin guidance section, improving the lethality of one of the U.S. Army’s most critical close combat weapons for the next decade. The work will be performed at Kratos’ Advanced Manufacturing Center in Birmingham, Alabama, with testing at U.S. Army Government facilities.

“Kratos has made the investments, built the credentialed team, and delivered the capabilities to win, execute, and deliver a production-ready seeker that keeps Javelin lethal for the Soldiers who depend on it,” said Michael Johns, Senior Vice President, Kratos SRE, Inc. “We are proud to support the U.S. Army in sustaining one of its most important close combat weapons, and this award is a reflection of everything Kratos stands for: affordable, mission-critical hardware, delivered.”

Kratos brings decades of missile seeker development heritage to this program and a vertically integrated manufacturing capability that positions the company to deliver production-ready hardware affordably and on schedule. The contract also directly supports the Secretary of War’s priority to strengthen the U.S. munitions industrial base.

About Kratos Defense & Security Solutions
Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS) is a technology, products, system and software company addressing the defense, national security, and global markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading-edge approaches and technology, not unproven bleeding-edge approaches, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low-cost future manufacturing which is a value-add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles; jet-powered unmanned aerial drone systems; advanced vehicles and rocket systems; propulsion systems for drones, missiles, loitering munitions, supersonic systems, spacecraft, and launch systems; C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter-UAS, directed energy, communication, and other systems; and virtual and augmented reality training systems for the warfighter. For more information, visit www.KratosDefense.com and follow Kratos on LinkedIn and X.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 29, 2025, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Press Contact: 
Claire Cantrell
[email protected]

Investor Relations: 
877-934-4687
[email protected]

Release – BODi Expands Retail Presence with Shakeology Now Available at The Vitamin Shoppe Nationwide; Launches New Flavor

Posted on by [email protected]
Placeholder Company

Research News and Market Data on BODI

August 6, 2026

Brings healthy daily protein and superfood nutrition to nearly 500 locations with the retail debut of Vanilla Whey, now with zero grams of added sugar

EL SEGUNDO, Calif.–(BUSINESS WIRE)– BODi (NASDAQ: BODI), the proactive wellness company delivering nutrition, supplements, and proven fitness programs that help people take control of their health inside and out, today announced that Shakeology is now available at The Vitamin Shoppe locations nationwide. The Vitamin Shoppe launch reinforces BODi’s commitment to making science-backed wellness more accessible to consumers across the U.S. The retail rollout includes the core flavors of Shakeology’s 0g Added Sugar line: Chocolate Vegan, Chocolate Whey, Vanilla Vegan, and the new, reformulated Vanilla Whey, all available in a convenient 7-serving bag.

BODi expands its retail presence with Shakeology now available at The Vitamin Shoppe nationwide.

BODi expands its retail presence with Shakeology now available at The Vitamin Shoppe nationwide.

Originally launched in 2009 with over a billion servings sold, Shakeology combines high-quality protein with fiber, prebiotics and probiotics, vitamins, minerals, digestive enzymes, adaptogens, antioxidants, greens, and more than 30 superfoods to help support energy, gut health, digestion and regularity, lean muscle, bone health, as well as a healthy immune system. It also helps protect against free radicals and oxidative stress, reduce cravings, and support weight loss, as demonstrated in a clinical study published in the Journal of Nutrition.

Consumers also report meaningful benefits from making Shakeology part of their daily routine. Based on a survey of Shakeology customers*:

  • 86% reported better digestion after one month
  • 84% said it helped reduce junk food cravings
  • 81% said it helped them feel full until their next meal
  • 74% reported increased energy throughout the day

“When we announced our partnership with The Vitamin Shoppe earlier this year, our goal was to make Shakeology more accessible than ever before,” said Carl Daikeler, co-founder and CEO of BODi. “Today, consumers can walk into stores nationwide and purchase Shakeology. Combined with the introduction of Vanilla Whey with zero grams of added sugar launching in retail for the first time, this represents another important step in bringing healthy, science-backed nutrition to more people.”

To locate the nearest The Vitamin Shoppe location, visit https://locations.vitaminshoppe.com. Shakeology is also available at more than 100 Sprouts Farmers Market locations nationwide. BODi continues to expand retail distribution through its strategic partnership with KeHE Distributors, whose network reaches more than 30,000 grocery, supermarket, natural, and online retail locations.

Consumers can also shop the full Shakeology line on BODi.com, including additional flavors such as 0g Added Sugar Café Latte, Cookies & Creamy, and Tropical Strawberry, as well as 14- and 30-serving bags.

*Based on a survey of 1,550 Shakeology customers who consumed Shakeology five or more times per week and exercised three times per week. Better digestion improvement based on 859 Shakeology customers who reported issues with digestion.

About BODi and The Beachbody Company

BODi is a proactive wellness company delivering nutrition, supplements and proven fitness programs that help people take control of their health inside and out. With nearly three decades of experience, BODi, formerly Beachbody, has evolved from a leader in home fitness into a comprehensive health and fitness ecosystem designed to help people achieve their goals and lead healthier, more fulfilling lives. Anchored by science-backed nutrition solutions like Shakeology and supported by its portfolio of proven fitness and habit-building programs, including P90X and INSANITY, BODi is creating a more accessible and effective path to long-term health.

Since its inception, BODi has supported more than 30 million customers in achieving lasting results. The company continues to innovate across nutrition and digital fitness to deliver simple, proven solutions for modern lifestyles.

To subscribe and shop, visit BODi.com. For company and investor information, please visit TheBeachbodyCompany.com.

About The Vitamin Shoppe®

The Vitamin Shoppe® is an omnichannel specialty retailer and wellness lifestyle company with the mission to provide customers with the most trusted products, guidance, and services that support health and performance in every stage of life. Founded in 1977 and headquartered in Secaucus, New Jersey, The Vitamin Shoppe today is an innovation-focused destination for first-to-market brands and breakthrough products, offering a comprehensive assortment of vitamins, supplements, sports nutrition, and on-the-go functional foods and beverages. Beyond hundreds of national brands, its offering includes the proprietary brands The Vitamin Shoppe®, Vthrive The Vitamin Shoppe®, BodyTech®, BodyTech® Elite, plnt®, ProBioCare®, and True Athlete®. The Company serves customers through more than 640 stores nationwide, providing personalized support from knowledgeable Health Enthusiast associates, and online at www.vitaminshoppe.com. It operates strategic partnerships in select international markets in Asia, South America, Central America, and the Caribbean. The Vitamin Shoppe proudly supports the health and wellness of communities through longstanding partnerships with Vitamin Angels and Team Red, White & Blue.

Media Relations:
[email protected]

Investor Relations:
[email protected]

Source: BODi

Release – Kelly Reports Second-Quarter 2026 Earnings

Posted on by [email protected]

Research News and Market Data on OCGN

August 6, 2026

PDF Version

TROY, Mich., Aug. 06, 2026 (GLOBE NEWSWIRE) — Kelly (Nasdaq: KELYA, KELYB), a leading specialty talent solutions provider, today announced results for the second quarter of 2026.

  • Q2 revenue of $1.0 billion, with year-over-year decline improving approximately 500 basis points (“bps”) versus the prior quarter; underlying revenue decline excluding previously disclosed discrete items improved 270 bps versus the prior quarter
  • Underlying revenue year-over-year performance reflects strength in the ETM and SET segments with each improved at least 300 bps versus the prior quarter, along with a 40 bps improvement for the Education segment
  • Q2 operating earnings of $16.1 million; $19.3 million of operating earnings on an adjusted basis
  • Q2 adjusted EBITDA of $31.1 million and adjusted EBITDA margin of 3.0%, improved 110 bps on a year-over-year basis versus the prior quarter resulting from stable year-over-year gross profit rate and continued SG&A discipline
  • Company increases its fiscal 2026 revenue outlook, now expecting a low-to-mid-single digit decline, and affirms its adjusted EBITDA margin expectation of modest year-over-year growth driven by accelerating underlying revenue growth and operating efficiencies

Chris Layden, chief executive officer, said, “In the second quarter, we measurably exceeded our guidance for both revenue and adjusted EBITDA margin driven by growing momentum from our growth and efficiency initiatives as well as constructive demand trends in parts of our portfolio. We delivered sequential improvements in each of our businesses as we continued to capitalize on organic growth drivers. Notably, Kelly’s adjusted EBITDA margin returned to 3.0% in the quarter, demonstrating our ability to generate operating leverage in pursuit of growth. Our progress strengthens our conviction in our strategy and reinforces our confidence in our expectation of further measurable improvement in our year-over-year performance as we progress through the second half of the year.”

Financial Results for the thirteen-week period ended June 28, 2026:

Revenue of $1.0 billion, a 5.8% decrease compared to the corresponding quarter of 2025. Discrete impacts associated with the previously disclosed reduced demand for U.S. federal government contractors in the SET segment and from three large commercial customers in the ETM segment totaled approximately 5.2%, resulting in an underlying revenue decline of approximately 0.6%. Underlying revenue performance includes overall growth from improved demand and new business in the ETM segment, including growth in staffing and each of the talent solutions specialties. Offsetting the growth was a measurably improved year-over-year decline within the SET segment which reflects continued year-over-year growth in the Telecom specialty and reduced declines in each of the SET specialties. SET revenue grew sequentially for the first time in over two years. Additionally, the Education segment showed an improved year-over-year decline which continues to be driven by delayed prior year contract decisions and declines in student enrollment in key markets.

Operating earnings of $16.1 million, compared to earnings of $22.2 million reported in the second quarter of 2025. Adjusted earnings1 were $19.3 million in the second quarter of 2026 and $24.6 million in the second quarter of 2025. Adjusted EBITDA1 of $31.1 million, a decrease of 15.9% versus the prior year period. Adjusted EBITDA margin of 3.0%, a decrease of 40 bps but improved 110 bps versus the prior quarter, reflects 10 bps lower gross margin partially offset by volume-related and structural expense management actions including benefits from our acquisition integration and technology modernization efforts. ETM showed year-over-year stability in its adjusted EBITDA margin while Education and SET both declined. Both ETM and SET improved their adjusted EBITDA margins measurably versus the prior quarter.

Income tax expense of $3.0 million, compared to income tax expense of $0.9 million reported in the second quarter of 2025. On an adjusted basis1, income tax expense of $3.8 million, compared to income tax expense of $2.5 million in the second quarter of 2025.

Earnings per share was $0.31 compared to earnings per share of $0.52 in the second quarter of 2025. On an adjusted basis1, earnings per share was $0.37 in the second quarter of 2026 compared to $0.54 per share in the corresponding quarter of 2025.

Financial Results for the 26-week period ended June 28, 2026:

Revenue of $2.1 billion, an 8.3% decrease compared to the corresponding period in 2025. Discrete impacts associated with the reduced demand for U.S. federal government contractors in the SET segment and from three large commercial customers in the ETM segment totaled approximately 6.3%, resulting in an underlying revenue decline of approximately 2.0%. Underlying revenue performance includes overall growth from improved demand in the ETM segment, including growth in each of the talent solutions specialties, along with growth in the Telecom specialty and improved performance in the Science and Engineering specialties within the SET segment. Offsetting this growth was continued lower demand in the other specialties within the SET segment, largely the Technology specialty, along with a decline in the Education segment driven by delayed prior year contract decisions and declines in student enrollment in key markets.

Operating earnings of $11.0 million, compared to earnings of $33.0 million reported over the same period in 2025. Adjusted earnings1 were $23.4 million in the first six months of 2026 and $46.7 million in the corresponding period of 2025. Adjusted EBITDA1 of $46.9 million, a decrease of 34.8% versus the prior year period. Adjusted EBITDA margin of 2.3%, a decrease of 90 bps, reflects near-term margin pressure in ETM, Education, and SET driven by lower gross margins and timing of revenue trends, partially offset by volume-related and structural expense management actions including benefits from our acquisition integration and technology modernization efforts.

Income tax expense of $2.2 million, compared to income tax expense of $2.7 million reported over the same period in 2025. On an adjusted basis1, income tax expense of $5.3 million, compared to income tax expense of $7.2 million in the corresponding period of 2025.

Earnings per share was $0.15, compared to earnings per share of $0.67 in the same period of 2025. On an adjusted basis1, earnings per share were $0.40 for the first six months of 2026 compared to $0.93 per share in the corresponding period of 2025.

1 Adjusted measures represent non-GAAP financial measures. Refer to our reconciliation of non-GAAP financial measures to the most closely related GAAP measure included in this document.

Financial Outlook For Fiscal 2026:

The Company’s 2026 financial outlook has improved for revenue and remains unchanged for Adjusted EBITDA margin relative to the initial view previously disclosed, assumes no material change in the macroeconomic environment in the coming quarters, and is as follows:

  • Third Quarter of 2026 – Expect year-over-year improvement relative to second quarter, with overall underlying revenue growth of 1% to 2%, and total revenue to be flat to a decline of 2% versus the prior year. Adjusted EBITDA margin in the low 2% range, representing 40 to 50 bps of year-over-year improvement relative to the prior year.
    • Outlook includes the seasonality impact of the Education business due to schools being out of session for the majority of the quarter which results in sequential revenue and profitability declines versus the second quarter.
  • Fourth Quarter of 2026 – Expect substantial improvement in year-over-year performance versus third quarter for both revenue and adjusted EBITDA margin resulting in mid-to-upper single digits revenue growth and approximately 200 bps of year-over-year adjusted EBITDA margin expansion resulting in adjusted EBITDA margin of approximately 4%.
    • Outlook includes the impact of an extra fiscal week in the fourth quarter, which benefits revenue growth by approximately 4 points in the quarter, but negatively impacts adjusted EBITDA.
  • Full Year 2026 – On a full year basis, expect low-to-mid single digit total revenue decline and a 10 to 20 bps year-over-year improvement in adjusted EBITDA margin.

Quarterly Cash Dividend:

Kelly also reported that on August 4, 2026, its board of directors declared a dividend of $0.075 per share. The dividend is payable on September 2, 2026 to stockholders of record as of the close of business on August 19, 2026.

In conjunction with its earnings release, Kelly has published a financial presentation and will host a live webcast of a conference call at 9 a.m. ET on August 6 to review the financial and operation results from the quarter. The presentation and a link to the live webcast will be accessible through the Company’s public website on the Investor Relations page under Events & Presentations. The webcast will be recorded, and a replay will be available within one hour of completion of the event through the same link as the live webcast.

Forward-Looking Statements:

This release contains statements that are forward looking in nature and, accordingly, are subject to risks and uncertainties. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about Kelly’s financial expectations, are forward-looking statements. Factors that could cause actual results to differ materially from those contained in this release include, but are not limited to, (i) changing market and economic conditions, (ii) disruption in the labor market and weakened demand for human capital resulting from technological advances, competitive pressures and pricing, loss of large corporate customers and government contractor requirements, (iii) the impact of laws and regulations (including federal, state and international tax laws), (iv) unexpected changes in claim trends on workers’ compensation, unemployment, disability and medical benefit plans, (v) litigation and other legal liabilities (including tax liabilities) in excess of our estimates, (vi) our ability to achieve our business’s anticipated growth strategies, (vii) our future business development, results of operations and financial condition, (viii) damage to our brands, (ix) dependence on third parties for the execution of critical functions, (x) conducting business in foreign countries, including foreign currency fluctuations, (xi) availability of temporary workers with appropriate skills required by customers, (xii) cyberattacks or other breaches of network or information technology security, and (xiii) other risks, uncertainties and factors discussed in this release and in the Company’s filings with the Securities and Exchange Commission. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. All information provided in this press release is as of the date of this press release and we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

About Kelly®

Kelly Services, Inc. (Nasdaq: KELYA, KELYB) helps companies recruit and manage skilled workers and helps job seekers find great work. Since inventing the staffing industry in 1946, we have become experts in the many industries and local and global markets we serve. With a network of suppliers and partners around the world, we connect approximately 375,000 people with work every year. Our suite of outsourcing and consulting services and solutions ensures companies have the people they need, when and where they are needed most. Headquartered in Troy, Michigan, we empower businesses and individuals to access limitless opportunities in industries such as science, engineering, technology, education, manufacturing, retail, finance, and energy. Revenue in 2025 was $4.3 billion. Learn more at kellyservices.com.

KLYA-FIN

ANALYST & MEDIA CONTACT:
Scott Thomas
(248) 251-7264
[email protected]

View full release here.

Release – Ocugen Provides Business Update with Second Quarter 2026 Financial Results

Posted on by [email protected]

Research News and Market Data on OCGN

August 6, 2026

PDF Version

Conference Call and Webcast Today at 8:30 a.m. ET

  • Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related macular degeneration (AMD); on track to initiate Phase 3 this quarter
  • Granted Regenerative Medicine Advanced Therapy (RMAT) designation by FDA for OCU410, enabling eligibility for priority review and accelerated approval
  • Signed a binding term sheet with Roots Pharmaceutical, and its strategic partner Al-Dhow International Holding, to negotiate an exclusive license for OCU400 in retinitis pigmentosa (RP) across the Middle East and North Africa (MENA) region
  • Successfully completed OCU400 Process Performance Qualification (PPQ) batches, supporting Biologics License Application (BLA) and commercial launch supplies
  • Closed $130.0 million convertible senior notes financing, extending cash runway into 2028
  • Remain on track to announce top-line results for two late-stage clinical programs, OCU400 for RP and OCU410ST for Stargardt disease in 1Q 2027 and 2Q 2027, respectively
  • Strengthened leadership team with the appointments of Mohamed Genead, M.D., M.Sc., as Chief Medical Officer and Chris Clark as Head of Corporate Communications

MALVERN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported second quarter 2026 financial results along with a general business update.

“The second quarter of 2026 marked a pivotal inflection point for Ocugen. We closed $130 million convertible senior notes financing, extending our cash runway into 2028, and signed a binding term sheet for exclusive license of OCU400 in retinitis pigmentosa across the Middle East and North Africa region,” said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen. “Ocugen is a leading gene therapy company, focused on vision loss diseases with significant unmet medical needs, with multiple catalysts through 2028 across three distinct retinal disease indications. As we advance toward key data milestones in the first half of 2027, we remain focused on creating long-term value for our patients and shareholders.”

Unlike traditional gene therapies that correct a single mutation, Ocugen’s modifier gene therapy platform targets master regulatory genes that control multiple gene networks of biological pathways, supporting a gene-agnostic approach applicable across a broad range of genetic mutations, as well as diseases with complex pathways such as dry AMD. This allows the Company to address large, underserved patient populations rather than narrow single-gene subsets. This platform underpins each of Ocugen’s three late-stage programs, which advanced meaningfully during the quarter.

Clinical Program Updates

OCU410 (GA)

  • Received FDA clearance for the Phase 3 registrational trial (ArMaDa3) for GA secondary to dry age-related macular degeneration, anchored by positive 12-month Phase 2 ArMaDa data (statistically significant 31% reduction in GA lesion growth versus control [patient population: lesion size ≥2.5 mm2 and ≤17.5 mm2], p<0.05, at the optimal dose planned for Phase 3)
  • Planned combined global Phase 3 trial of approximately 237 subjects powered at 95% for primary end point on track to initiate this quarter, with BLA and MAA filings targeted for 2028
  • Granted Regenerative Medicine Advanced Therapy RMAT designation by FDA, enabling eligibility for priority review and accelerated approval
  • GA affects approximately 2 to 3 million people in the U.S. and Europe

OCU410ST (Stargardt disease)

  • Completed enrollment and dosing of 63 subjects ahead of schedule, in less than nine months, in the pivotal Phase 2/3 GARDian3 trial evaluating OCU410ST in patients with all mutations of Stargardt disease
  • Topline results anticipated in the second quarter of 2027, with a BLA submission to follow mid-2027
  • Holds Orphan Drug and Rare Pediatric Disease Designations from the FDA and Orphan Medicinal Product Designation and Advanced Therapy Medicinal Product classification from the EMA
  • Stargardt disease affects approximately 100,000 patients across the U.S. and Europe, with no approved therapies globally

OCU400 (RP)

  • Completed enrollment in liMeliGhT (N=140), the first and largest genetic medicine registrational trial for broad RP patients, spanning more than 30 genetic mutations
  • FDA feedback confirmed that the path to rolling BLA submission remains tied to topline data expected in the first quarter of 2027, and the company is advancing preparation accordingly, including successfully completing Process Performance Qualification (PPQ) batches
  • Approximately 300,000 people in the U.S. and Europe are living with RP

Corporate Updates

  • Closed the offering of $130.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034, including the full exercise of the $15.0 million over-allotment option, for net proceeds of approximately $112.5 million
    • Approximately $32.7 million of net proceeds was used to fully retire the Avenue Capital loan, eliminating 12.25% interest-rate debt from the Company’s capital structure
    • The offering extends Ocugen’s cash runway into 2028
  • Signed a binding term sheet with Roots Pharmaceutical to negotiate an exclusive OCU400 license in the MENA region, with up to $255 million in sales milestones and a 22% royalty on net sales, as well as moderate upfront payment to Ocugen
  • Ocugen appointed two new members to its leadership team
    • Mohamed Genead, M.D., M.Sc., was named Chief Medical Officer on June 11, 2026. Dr. Genead is an ophthalmologist and retina specialist with more than 20 years of experience in ophthalmology and gene therapy, having previously served as Co-Founder and Chief Executive Officer of Aviceda Therapeutics and in senior leadership roles at GenSight Biologics, Biogen, and Allergan
    • Chris Clark was named Vice President, Corporate Communications on July 16, 2026. He has more than 20 years of communications and investor relations experience in the pharmaceutical and biopharmaceutical industries, having held leadership positions at Bausch + Lomb, Idorsia Pharmaceuticals, and Pfizer, as well as communications and investor relations roles at Novo Nordisk, Bristol Myers Squibb, Endo Pharmaceuticals, and Johnson & Johnson

Second Quarter 2026 Financial Results

  • The Company’s cash, cash equivalents, and restricted cash totaled $100.4 million as of June 30, 2026, compared to $32.2 million as of March 31, 2026.
  • The Company had 339.0 million shares of common stock outstanding as of June 30, 2026.
  • Total operating expenses for the three months ended June 30, 2026, were $17.9 million and included research and development expenses of $10.7 million and general and administrative expenses of $7.2 million, compared to total operating expenses for the three months ended June 30, 2025, of $15.2 million that included research and development expenses of $8.4 million and general and administrative expenses of $6.8 million.
  • Ocugen reported a $0.07 net loss per common share for the three months ended June 30, 2026, compared to a $0.05 net loss per common share for the three months ended June 30, 2025.

Conference Call and Webcast Details
Ocugen has scheduled a conference call and webcast for 8:30 a.m. ET today to discuss the financial results and recent business highlights. Ocugen’s senior management team will host the call, which will be open to all listeners. There will also be a question-and-answer session following the prepared remarks.

Ocugen has scheduled a conference call and webcast for 8:30 a.m. ET today to discuss the financial results and recent business highlights. Ocugen’s senior management team will host the call, which will be open to all listeners. There will also be a question-and-answer session following the prepared remarks.

Attendees are invited to participate on the call using the following details:

Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callers
Conference ID: 2222566
Webcast: Available on the events section of the Ocugen investor site

A replay of the call and archived webcast will be available on the Ocugen investor site.

About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology company developing gene therapies for blindness diseases. The Company’s breakthrough modifier gene therapy platform has the potential to address significant unmet medical needs across large patient populations through a gene-agnostic approach. Unlike traditional gene therapies and gene-editing technologies that target a single gene mutation, Ocugen’s modifier gene therapies are designed to address the underlying disease biology by restoring balance across multiple gene networks. The Company is currently advancing programs for inherited retinal diseases and other causes of blindness that affect millions worldwide, including retinitis pigmentosa, Stargardt disease, and geographic atrophy, an advanced form of dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on LinkedIn and X.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, strategy, business plans and objectives for Ocugen’s clinical programs, plans and timelines for the preclinical and clinical development of Ocugen’s product candidates, including the therapeutic potential, clinical benefits and safety thereof, expectations regarding timing, success and data announcements of current ongoing preclinical and clinical trials, including the timing of enrollment and data readouts, the ability to initiate new clinical programs, Ocugen’s financial condition and expected cash runway into 2028, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, statements regarding potential market size and commercial possibilities of Ocugen’s product candidates, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing may not be predictive of the results or success of later clinical trials; and that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our annual and periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contacts:

Investors:
Candice Masse
astr partners
[email protected]

Media:
Chris Clark
[email protected]

View full release here.